← Evidence map

ArticleCancer medicine2026

Optimizing the ER Cutoff in HER2-Positive Breast Cancer: ER ≥ 50% Predicts Low pCR Rates and Resistance to Antibody-Drug Conjugates in the Neoadjuvant Setting.

Tian Du et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Optimizing the ER Cutoff in HER2-Positive Breast Cancer: ER ≥ 50% Predicts Low pCR Rates and Resistance to Antibody-Drug Conjugates in the Neoadjuvant Setting. | OpenQuestion